The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study

Jason C Yam; Yuning Jiang; Jackie Lee; Sherie Li; Yuzhou Zhang; Wen Sun; Nan Yuan; Yu Meng Wang; Benjamin Hon Kei Yip; Ka Wai Kam; Hei-Nga Chan; Xiu Juan Zhang; Alvin L Young; Clement C Tham; Carol Y Cheung; Wai Kit Chu; Chi Pui Pang; Li Jia Chen

doi:10.1016/j.ajo.2021.12.014

The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study

Am J Ophthalmol. 2022 May:237:130-138. doi: 10.1016/j.ajo.2021.12.014. Epub 2021 Dec 21.

Authors

Jason C Yam¹, Yuning Jiang², Jackie Lee², Sherie Li², Yuzhou Zhang², Wen Sun³, Nan Yuan², Yu Meng Wang², Benjamin Hon Kei Yip³, Ka Wai Kam⁴, Hei-Nga Chan², Xiu Juan Zhang², Alvin L Young⁴, Clement C Tham⁵, Carol Y Cheung², Wai Kit Chu⁶, Chi Pui Pang⁶, Li Jia Chen⁷

Affiliations

¹ From the Department of Ophthalmology and Visual Sciences (J.C.Y., Y.J., J.L., S.L., Y.Z., N.Y., Y.M.W., K.W.K., H.-N.C., X.J.Z., A.L.Y., C.C.T., C.Y.C., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong, Hong Kong;; Hong Kong Eye Hospital, (J.C.Y., C.C.T.), Hong Kong; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, (J.C.Y., K.W.K., A.L.Y.,C.C.T., L.J.C.), Hong Kong; Hong Kong Hub of Paediatric Excellence (J.C.Y., C.C.T., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong; Department of Ophthalmology, Hong Kong Children's Hospital (J.C.Y.), Hong Kong. Electronic address: yamcheuksing@gmail.com.
² From the Department of Ophthalmology and Visual Sciences (J.C.Y., Y.J., J.L., S.L., Y.Z., N.Y., Y.M.W., K.W.K., H.-N.C., X.J.Z., A.L.Y., C.C.T., C.Y.C., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong, Hong Kong.
³ Jockey Club School of Public Health and Primary Care (W.S., B.H.K.Y.), The Chinese University of Hong Kong, Hong Kong, China.
⁴ From the Department of Ophthalmology and Visual Sciences (J.C.Y., Y.J., J.L., S.L., Y.Z., N.Y., Y.M.W., K.W.K., H.-N.C., X.J.Z., A.L.Y., C.C.T., C.Y.C., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong, Hong Kong;; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, (J.C.Y., K.W.K., A.L.Y.,C.C.T., L.J.C.), Hong Kong.
⁵ From the Department of Ophthalmology and Visual Sciences (J.C.Y., Y.J., J.L., S.L., Y.Z., N.Y., Y.M.W., K.W.K., H.-N.C., X.J.Z., A.L.Y., C.C.T., C.Y.C., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong, Hong Kong;; Hong Kong Eye Hospital, (J.C.Y., C.C.T.), Hong Kong; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, (J.C.Y., K.W.K., A.L.Y.,C.C.T., L.J.C.), Hong Kong; Hong Kong Hub of Paediatric Excellence (J.C.Y., C.C.T., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong.
⁶ From the Department of Ophthalmology and Visual Sciences (J.C.Y., Y.J., J.L., S.L., Y.Z., N.Y., Y.M.W., K.W.K., H.-N.C., X.J.Z., A.L.Y., C.C.T., C.Y.C., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong, Hong Kong;; Hong Kong Hub of Paediatric Excellence (J.C.Y., C.C.T., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong.
⁷ From the Department of Ophthalmology and Visual Sciences (J.C.Y., Y.J., J.L., S.L., Y.Z., N.Y., Y.M.W., K.W.K., H.-N.C., X.J.Z., A.L.Y., C.C.T., C.Y.C., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong, Hong Kong;; Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, (J.C.Y., K.W.K., A.L.Y.,C.C.T., L.J.C.), Hong Kong; Hong Kong Hub of Paediatric Excellence (J.C.Y., C.C.T., W.K.C., C.P.P., L.J.C.), The Chinese University of Hong Kong.

PMID: 34942105
DOI: 10.1016/j.ajo.2021.12.014

Abstract

Purpose: To evaluate longitudinal changes in subfoveal choroidal thickness (SFChT) among children receiving atropine 0.05%, 0.025%, or 0.01% over 2 years and their associations with treatment outcomes in myopia control.

Design: Double-blinded randomized controlled trial.

Methods: SFChT was measured at 4-month intervals using spectral domain optical coherence tomography. Cycloplegic spherical equivalent (SE), axial length (AL), best-corrected visual acuity, parental SE, outdoor time, near work diopter hours, and treatment compliance were also measured.

Results: 314 children were included with qualified choroidal data. The 2-year changes in SFChT from baseline were 21.15 ± 32.99 µm, 3.34 ± 25.30 µm, and -0.30 ± 27.15 µm for the atropine 0.05%, 0.025%, and 0.01% groups, respectively (P < .001). A concentration-dependent response was observed, with thicker choroids at higher atropine concentrations (β = 0.89, P < .001). Mean SFChT thickness significantly increased at 4 months in the atropine 0.025% (P = .001) and 0.05% groups (P < .001) and then remained stable until the end of the second year (P > .05 for all groups). Over 2 years, an increase in SFChT was associated with slower SE progression (β = 0.074, P < .001) and reduced AL elongation (β = -0.045, P < .001). In the mediation analysis, 18.45% of the effect on SE progression from atropine 0.05% was mediated via its choroidal thickening.

Conclusions: Low concentration atropine induced a choroidal thickening effect along a concentration-dependent response throughout the treatment period. The choroidal thickening was associated with a slower SE progression and AL elongation among all the treatment groups. Choroidal response can be used for assessment of long-term treatment outcomes and as a guide for concentration titrations of atropine.

Publication types

Randomized Controlled Trial

MeSH terms

Atropine* / therapeutic use
Axial Length, Eye
Child
Choroid
Humans
Myopia* / diagnosis
Myopia* / drug therapy
Refraction, Ocular
Tomography, Optical Coherence

Substances

Atropine